Q2 2021 Results - Reimagining Medicine
Participants
Financial performance
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
ABL001
-
Specific, allosteric Bcr-Abl kinase inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
NCT03106779 ASCEMBL (CABL001A2301)
Chronic myeloid leukaemia (CML)
Phase 3
233
Major Molecular Response (MMR) rate at 24 weeks
ABL001 40 mg bid
Bosutinib 500 mg
Patients with chronic myelogenous leukemia in chronic phase, previously treated
with 2 or more tyrosine kinase inhibitors
Q3-2020 (actual)
Hochhaus A., et al. [Efficacy and Safety Results from ASCEMBL, a Multicenter,
Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs
Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase
(CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs), LBA-4]
ASH 2020
Manuscript submission H1-2021
96 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation